Suppression of pentylenetetrazol-induced seizures and c-fos expression in mouse brain by L-carnitine

Journal of Occupational Health

Volumn 42, Issue 3, 2000, Pages 119-123

  Iryo, Yoshihisa ^a   Matsuoka, Masato ^a   Igisu, Hideki ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

C fos; Carnitine; Immediate early genes; Pentylenetetrazol; Seizures

Indexed keywords

CARNITINE; PENTETRAZOLE; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG INDUCED DISEASE; GENE EXPRESSION; LATENT PERIOD; MOUSE; NONHUMAN; ONCOGENE C FOS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEIZURE;

EID: 0033920301     PISSN: 13419145     EISSN: None     Source Type: Journal    
DOI: 10.1539/joh.42.119     Document Type: Article

References (25)

1. Kilburn KH. Chemically exposed patients. In: Chemical brain injury. New York: Van Nostrand Reinhold, 1998: 62-91.
2. Rogawski MA, Porter RJ. Antiepileptic drugs: pharmacological mechanisms and clinical efficacy with consideration of promising developmental stage compounds. Pharmacol Rev 1990; 42: 223-286.
3. Yu Z, Iryo Y, Matsuoka M, Igisu H, Ikeda M. Suppression of pentylenetetrazol-induced seizures by carnitine in mice. Naunyn-Schmiedeberg's Arch Pharmacol 1997; 355: 545-549.
4. Bremer J. Carnitine: metabolism and functions. Physiol Rev 1983; 63: 1420-1480.
5. Nezu J, Tamai I, Oku A, et al. Primary systemic carnitine deficiency is caused by mutations in a gene encoding sodium ion-dependent carnitine transporter. Nature Genet 1999; 21: 91-94.
6. Koizumi A, Nozaki J, Ohura T, et al. Genetic epidemiology of the carnitine trasporter OCTN2 gene in a Japanese population and phenotypic characterization in Japanese pedigrees with primary systemic carnitine deficiency. Hum Mol Genet 1999; 8: 2247-2254.
7. Ohashi R, Tamai I, Yabuuchi H, et al. Na+-depencent carnitine transport by organic cation transporter (OCTN2): Its pharmacological and toxicological relevance. J Pharmacol Exp Ther 1999; 291: 778-784.
8. Pons R, De Vivo D. Primary and secondary carnitine deficiency syndromes. J Child Neurol 1995; 10 (Suppl): 2S8-2S24.
9. Kanazu T, Yamaguchi T. Comparison of in vitro carnitine and glycine conjugation with branched-side chain and cyclic side chain carboxylic acids in rats. Drug Met Disp 1997; 25: 149-153.
10. Morgan JI, Cohen DR, Hempstead JL, Curran T. Mapping patterns of c-fos expression in the central nervous system after seizure. Science 1987; 237: 192-197.
11. Erdtmann-Vourliotis M, Riechert U, Mayer P, Grecksch G, Hollt V. Pentylenetetrazole (PTZ)-induced c-fos expression in the hippocampus of kindled rats is suppressed by concomitant treatment with naloxone. Brain Res 1998; 792: 299-308.
12. Matsuoka M, Matsumura H, Igisu H, Hori H, Tanaka I. Effects of single exposure to toluene vapor on the expression of immediate early genes and GFAP gene in the mouse brain. Arch Toxicol 1997; 71: 722-723.
13. Matsuoka M, Igisu H, Kohriyama K, Inoue N. Suppression of neurotoxicity of ammonia by L-carnitine. Brain Res 1991; 567: 328-331.
14. Lu XC, Tortella FC, Ved HS, Garcia GE, Dave JR. Neuroprotective role of c-fos antisense oligonucleotide: in vitro and in vivo studies. Neuroreport 1997; 8: 2925-2929.
15. Katsumori H, Hashimoto K, Tomitaka S, Osawa M, Minabe Y. Acute effect of c-fos antisense oligodeoxynucleotide on hippocampal partial seizures elicited by electrical stimulation in rats. Neurosci Lett 1997; 225: 149-152.
16. Lukasiuk K, Kaczmarek L. AP-1 and CRE DNA binding activities in rat brain following pentylenetetrazole induced seizures. Brain Res 1994; 643: 227-233.
17. Rebouche CJ, Engel AG. Tissue distribution of carnitine biosynthetic enzyme in man. Biochim Biophys Acta 1980; 630: 22-29.
18. O'Connor JE, Costell M, Miguez M-P, Grisolia S. Influence of the route of administration on the protective effect of L-carnitine on acute hyperammonemia. Biochem Pharmacol 1986; 18: 3173-3176.
19. Roe CR, Coates PM. Mitochondrial fatty acid oxidation disorders. In: Scriver CR, Beaudet AL, Sly WS, Valle D. The metabolic and molecular basis of inherited disease. New York: McGraw-Hill, 1995: 1501-1533.
20. Fariello RG, Shug AL. Competitive inhibition by 3-aminopropanesulfonic acid and γ-aminobutyric acid of carnitine transport in the rat brain slices. Biochem Pharmacol 1981; 30: 1012-1013.
21. Tamai I, Ohashi R, Nezu J et al. Molecular and functional identification of sodium ion-dependent, high affinity human carnitine transporter OCTN2. J Biol Chem 1998; 273: 20378-20382.
22. Matsuoka M, Igisu H. Preservation of energy metabolites by carnitine in the mouse brain under ischemia. Brain Res 1992; 590: 334-336.
23. 31P spectroscopy study of treated and untreated recovery of rat partial brain ischemia. Magn Reson Med 1995; 34: 542-547.
24. O'Connor JE, Costell M, Grisolía S. Protective effect of L-carnitine on hyperammonemia. FEBS Lett 1984; 166: 331-334.
25. Spagnoli A, Lucca U, Menasce G, et al. Long-term acetyl-L-carnitine treatment in Alzheimer's disease. Neurology 1991; 41: 1726-1732.